Therefore, the anti-tumor efficacy of Lm-LLO-CD105A in this RCC model is likely dependent, in large part, on the induction of an anti-tumor immune response mediated by cytotoxic CD8+ T cells. The gene discussed is CD8A; the disease is renal cell carcinoma.